Jump to content

Main menu Navigation ●Main page ●Contents ●Current events ●Random article ●About Wikipedia ●Contact us ●Donate Contribute ●Help ●Learn to edit ●Community portal ●Recent changes ●Upload file

●Create account ●Log in ●Create account ● Log in Pages for logged out editors learn more ●Contributions ●Talk

(Top) 1 See also 2 References

Serlopitant

●فارسی Edit links ●Article ●Talk ●Read ●Edit ●View history Tools Actions ●Read ●Edit ●View history General ●What links here ●Related changes ●Upload file ●Special pages ●Permanent link ●Page information ●Cite this page ●Get shortened URL ●Download QR code ●Wikidata item Print/export ●Download as PDF ●Printable version In other projects ●Wikimedia Commons Appearance From Wikipedia, the free encyclopedia

Serlopitant
Clinical data

Routes of administration	By mouth
ATC code	None
Identifiers
IUPAC name 3-[(3aR,4R,5S,7aS)-5-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy}-4-(4-fluorophenyl)octahydro-2H-isoindol-2-yl]cyclopent-2-en-1-one
CAS Number	860642-69-9
PubChem CID	23653789
ChemSpider	24686685
UNII	277V92K32B
KEGG	D09378
ChEMBL	ChEMBL447955
CompTox Dashboard (EPA)	DTXSID701006599
Chemical and physical data
Formula	C₂₉H₂₈F₇NO₂
Molar mass	555.537 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES C[C@H](C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)O[C@H]2CC[C@@H]3CN(C[C@H]3[C@@H]2C4=CC=C(C=C4)F)C5=CC(=O)CC5
InChI InChI=1S/C29H28F7NO2/c1-16(19-10-20(28(31,32)33)12-21(11-19)29(34,35)36)39-26-9-4-18-14-37(23-7-8-24(38)13-23)15-25(18)27(26)17-2-5-22(30)6-3-17/h2-3,5-6,10-13,16,18,25-27H,4,7-9,14-15H2,1H3/t16-,18-,25-,26+,27+/m1/s1 Key:FLNYCRJBCNNHRH-OIYLJQICSA-N

Serlopitant (INN,^[1] codenamed VPD-737) is a drug which acts as an NK₁ receptor antagonist. It was assessed in clinical trials for the treatment of urinary incontinence and overactive bladder, but while it was superior to placebo it provided no advantage over existing approved drugs, and was not approved for further development for this indication.^[2]^[3] Serlopitant is now undergoing clinical trials for the treatment of chronic pruritus (itch)^[4]

References[edit]

^ "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 62" (PDF). World Health Organization. 2009. pp. 261–2. Retrieved 17 November 2016.

^ Frenkl TL, Zhu H, Reiss T, Seltzer O, Rosenberg E, Green S (August 2010). "A multicenter, double-blind, randomized, placebo controlled trial of a neurokinin-1 receptor antagonist for overactive bladder". The Journal of Urology. 184 (2): 616–22. doi:10.1016/j.juro.2010.03.147. PMID 20639026.

^ Payton S (August 2010). "Urinary incontinence: Neurokinin receptor antagonist inferior to tolterodine for OAB". Nature Reviews. Urology. 7 (8): 418. doi:10.1038/nrurol.2010.105. PMID 20726068. S2CID 33202979.

^ "For Irritating Itch, a Promising Option Under Scrutiny".

Neurokinin receptor modulators

NK₁

Agonists: Substance P

NK₂

Agonists: Neurokinin A

NK₃

Agonists: Neurokinin B
Senktide

This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Serlopitant&oldid=1147977838" Categories: ●Drugs not assigned an ATC code ●NK1 receptor antagonists ●Trifluoromethyl compounds ●Fluoroarenes ●Ethers ●Genito-urinary system drug stubs Hidden categories: ●Articles with short description ●Short description matches Wikidata ●Chemical pages without DrugBank identifier ●Drugs with no legal status ●Articles containing unverified chemical infoboxes ●All stub articles ●This page was last edited on 3 April 2023, at 09:36 (UTC). ●Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization. ●Privacy policy ●About Wikipedia ●Disclaimers ●Contact Wikipedia ●Code of Conduct ●Developers ●Statistics ●Cookie statement ●Mobile view